{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fibrodysplasia+Ossificans+Progressiva", "query": { "condition": "Fibrodysplasia Ossificans Progressiva" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 19, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fibrodysplasia+Ossificans+Progressiva&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T18:00:45.499Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02745158", "title": "The Fibrodysplasia Ossificans Progressiva (FOP) Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fibrodysplasia Ossificans Progressiva (FOP)" ], "interventions": [], "intervention_types": [], "sponsor": "The International FOP Association", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 800, "start_date": "2015-07", "completion_date": "2040-12-31", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-06-10T18:00:45.499Z", "location_count": 1, "location_summary": "North Kansas City, Missouri", "locations": [ { "city": "North Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02745158" }, { "nct_id": "NCT06508021", "title": "A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Fibrodysplasia Ossificans Progressiva" ], "interventions": [ { "name": "Andecaliximab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ashibio Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 92, "start_date": "2024-10-25", "completion_date": "2029-02-04", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-06-10T18:00:45.499Z", "location_count": 3, "location_summary": "San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06508021" }, { "nct_id": "NCT02279095", "title": "An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fibrodysplasia Ossificans Progressiva" ], "interventions": [ { "name": "Palovarotene dose level 1", "type": "DRUG" }, { "name": "Palovarotene dose level 2", "type": "DRUG" }, { "name": "Palovarotene dose level 3", "type": "DRUG" }, { "name": "Palovarotene dose level 4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clementia Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "6 Years to 65 Years" }, "enrollment_count": 58, "start_date": "2014-10-09", "completion_date": "2022-09-20", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-06-10T18:00:45.499Z", "location_count": 3, "location_summary": "San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02279095" }, { "nct_id": "NCT05090891", "title": "To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fibrodysplasia Ossificans Progressiva (FOP)" ], "interventions": [ { "name": "INCB000928", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "2 Years to 99 Years" }, "enrollment_count": 98, "start_date": "2022-05-05", "completion_date": "2033-01-20", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-10T18:00:45.499Z", "location_count": 3, "location_summary": "Rochester, Minnesota • Philadelphia, Pennsylvania", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05090891" }, { "nct_id": "NCT05099445", "title": "Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Impairment", "Hemodialysis" ], "interventions": [ { "name": "INCB000928", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "82 Years", "sex": "ALL", "summary": "18 Years to 82 Years" }, "enrollment_count": 48, "start_date": "2021-12-14", "completion_date": "2023-02-27", "has_results": false, "last_update_posted_date": "2023-05-15", "last_synced_at": "2026-06-10T18:00:45.499Z", "location_count": 5, "location_summary": "Rialto, California • Hialeah, Florida • Miami, Florida + 2 more", "locations": [ { "city": "Rialto", "state": "California" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05099445" }, { "nct_id": "NCT02322255", "title": "A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fibrodysplasia Ossificans Progressiva" ], "interventions": [], "intervention_types": [], "sponsor": "Clementia Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 114, "start_date": "2014-12-18", "completion_date": "2020-04-09", "has_results": false, "last_update_posted_date": "2020-06-26", "last_synced_at": "2026-06-10T18:00:45.499Z", "location_count": 2, "location_summary": "San Francisco, California • Philadelphia, Pennsylvania", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02322255" }, { "nct_id": "NCT03312634", "title": "An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fibrodysplasia Ossificans Progressiva" ], "interventions": [ { "name": "Palovarotene", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clementia Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 107, "start_date": "2017-11-30", "completion_date": "2022-09-07", "has_results": true, "last_update_posted_date": "2023-11-29", "last_synced_at": "2026-06-10T18:00:45.499Z", "location_count": 4, "location_summary": "San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03312634" }, { "nct_id": "NCT04665323", "title": "An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fibrodysplasia Ossificans Progressiva" ], "interventions": [], "intervention_types": [], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 411, "start_date": "2021-01-18", "completion_date": "2021-04-30", "has_results": false, "last_update_posted_date": "2021-05-21", "last_synced_at": "2026-06-10T18:00:45.499Z", "location_count": 1, "location_summary": "Cambridge, Massachusetts", "locations": [ { "city": "Cambridge", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04665323" }, { "nct_id": "NCT02066324", "title": "Urine Sample Collection From FOP Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fibrodysplasia Ossificans Progressiva" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "5 Years to 35 Years" }, "enrollment_count": 25, "start_date": "2013-11", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2015-03-12", "last_synced_at": "2026-06-10T18:00:45.499Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02066324" }, { "nct_id": "NCT05394116", "title": "A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fibrodysplasia Ossificans Progressiva" ], "interventions": [ { "name": "Garetosmab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2022-11-21", "completion_date": "2029-02-27", "has_results": false, "last_update_posted_date": "2026-01-16", "last_synced_at": "2026-06-10T18:00:45.499Z", "location_count": 2, "location_summary": "Los Angeles, California • Nashville, Tennessee", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05394116" } ] }